RankAlpha logo
Back to Rankings

AMGN

AmgenD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Earnings surprise screen
69Speculative2026-11-03 amc

AMGN has a meaningful positive whisper gap ($6.07 versus $5.70 consensus) and management previously raised 2026 revenue and EPS guidance; strong growth-driver sales support the operating story. The stock closed near its three-session high, but recent volume did not establish 1.5x accumulation, XLV was slightly weaker, and the higher informal bar plus spending and loss-of-exclusivity concerns temper the setup.

Revision
20
Revenue
10
Business
15
Price
18
Volume
0
Risk
6
Required signals: None marked positive
Preferred signals: None marked positive
Risk flags: No verified 20-session relative-strength calculation versus XLV., No recent session verified above 1.5x normal volume; the latest session was below that threshold.
Screen as of 2026-10-28. Window 2026-10-28 to 2026-11-03.

Setup hits (3d)

Net Neutral

0 setup hits in the last 3 trading days, 0 bullish, 0 bearish, net strength weak.

Review the highest-weight setup hits and confirm with price action before acting.

Total Hits
0
Last 3d
Bullish
0
0% of hits
Bearish
0
0% of hits
Net Bias
Net Neutral
Balanced
Top Strength
weak
Weighted strength
Bullish setup hits
Sorted by strength

No setup hits found in the last 3 trading days.

Recent setup history
Date
Bullish
Bearish
Total
10.27
Latest
0
0
0
10.26
1d ago
0
0
0
10.25
2d ago
0
0
0
Bullish hitBearish hit- No activity
Open full setup hits view

Setup hits are derived from RankAlpha screener rules firing within the last 3 trading days. Net bias reflects the weighted balance of bullish vs bearish hits.